HOME >> BIOLOGY >> NEWS
Anti-HIV drugs save vision, improve outlook for AIDS patients

A new study from Johns Hopkins researchers shows the multiple anti-HIV drug regimen called highly active antiretroviral therapy (HAART) saves eyesight as well as lives. A second study led by Johns Hopkins researchers finds that among AIDS patients with longstanding vision problems, those who took HAART reported higher overall quality of life.

The Johns Hopkins team reported in the April issue of Archives of Ophthalmology that AIDS patients who received HAART had a 75 percent lower risk of visual impairment than those who did not. In the second, multicenter study, published in the May issue of the journal Ophthalmology, AIDS patients with vision loss reported a lower vision-related quality of life, although those who took HAART reported higher overall quality of life than those who did not.

AIDS patients are at high risk of vision loss from cytomegalovirus (CMV) retinitis, an infectious disease of the retina. Symptoms include "floaters" and permanent loss of central vision. With HAART, which became available in 1995, many patients' immune systems seem to recover enough to control CMV retinitis. The condition at one time affected 30 percent of patients at some point during their lives, but has probably decreased to 7.5 percent with the advent of HAART, says John H. Kempen, M.D., Ph.D., lead author of both studies and assistant professor of ophthalmology and epidemiology. By the time CMV is diagnosed, Kempen says, many AIDS patients are already legally blind or have significant vision loss.

"AIDS patients should take HAART as soon as and as much as they can," he says. "HAART often can save both their life and their vision."

In the Archives study, Kempen and his team evaluated 648 AIDS patients seen at the Wilmer Eye Institute at Johns Hopkins between August 1983 and March 2000. Seventeen percent had 20/200 vision (the definition of legal blindness) at the time of diagnosis, while 33 percent had 20/50 vision -- poor eno
'"/>

Contact: Karen Blum
kblum@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
13-May-2003


Page: 1 2 3

Related biology news :

1. Anti-HIV statisticians win $1.125 million NIH Merit Award
2. New Anti-HIV Therapies Needed To Eradicate HIV
3. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
4. New and better drugs for tuberculosis goal of UH professor
5. New technique helps scientists reveal interactions between genes and drugs
6. New database to help develop AIDS drugs
7. Orange, tangerine peels could be better than drugs for lowering cholesterol
8. New papillomavirus target could lead to specific antiviral drugs for precancerous cervical lesions
9. Newer drugs more effective at curing strep throat than penicillin
10. New software developed at Rensselaer predicts promising ingredients for new drugs
11. Protein abundant in human tumors confers resistance to anticancer drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... PROVIDENCE, R.I. , April 25, 2017 /PRNewswire/ ... EpiVax, Inc. ("EpiVax") has licensed its novel immune-modulating technology ... in autoimmune disease and allergy. Tregitopes, ... discovered in human immunoglobulin by EpiVax CEO ... Martin. Similar to intravenous immunoglobulin G, an autoimmune ...
(Date:4/25/2017)... ... April 25, 2017 , ... Covalent ... Covalent’s Analytical Services unit provides high-quality data to clients, both faster ... hours of receipt. There are no price premiums, and customers are welcome to ...
(Date:4/24/2017)... ... April 24, 2017 , ... It ... a cellular milieu; however, the broad application of this cellular target engagement concept ... sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for particular applications, ...
(Date:4/21/2017)... COLORADO (PRWEB) , ... April 21, 2017 , ... ... Awards recognized outstanding manufactures in 10 categories with over 30 nominees and well ... in Manufacturing presented the new award and the event was hosted by CompanyWeek ...
Breaking Biology Technology:
Cached News: